Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.61 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 2/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 5/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | MARK3 | P27448 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30053533 | 1.00 | PDPK1 (0.61) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL28252150 | 0.79 | EGFR (0.54) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL378320 | 0.78 | CDK2 (0.44) | PDPK1GDALRRK2LMNAXDH | |
| SCHEMBL19780 | 0.77 | PDPK1 (0.66) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL28251818 | 0.77 | PDPK1 (0.47) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| 2,6-Diaminopurine SCHEMBL29143272 | 0.77 | PDPK1 (0.92) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL29375916 | 0.77 | PDPK1 (0.66) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| 2,6-Diaminopurine SCHEMBL24053 | 0.76 | PDPK1 (1.00) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL28004928 | 0.75 | PDPK1 (0.45) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| 2,6-Diaminopurine SCHEMBL8757979 | 0.75 | PDPK1 (0.96) | PDPK1GDAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730485-B2 | DETECTION OF BINDING DOMAIN IN POLYPEPTIDE; OBTAIN POLYPEPTIDE, INCUBATE WITH LIGAND, EXPOSE SPECTRUM ANALYSIS, DETECT BINDING DOMAIN IN PROTEIN | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| US-6730484-B2 | POLYNUCLEOTIDE OR POLYPEPTIDE, AS WELL AS METHODS FOR DETERMINING WHETHER A PARTICULAR SITE IN A TARGET MOLECULE IS AT OR NEAR THE LIGAND BINDING SITE, ARE PROVIDED. LIGAND BINDING AFFINITIES CORRESPONDING TO BOTH THE TARGET MOLECULE | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| US-20030165915-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | claimed |
| US-20030077630-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | claimed |
| US-20030013113-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240060140-A1 | IGH REARRANGEMENTS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4267767-A1 | IGH REARRANGEMENTS AND USES THEREOF | Foundation Medicine, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4223770-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-2914622-B1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUND MEDICINE INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-2914621-B1 | NOVEL NTRK1 FUSION MOLECULES AND USES THEREOF | FOUND MEDICINE INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-6730485-B2 | DETECTION OF BINDING DOMAIN IN POLYPEPTIDE; OBTAIN POLYPEPTIDE, INCUBATE WITH LIGAND, EXPOSE SPECTRUM ANALYSIS, DETECT BINDING DOMAIN IN PROTEIN | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-6730484-B2 | POLYNUCLEOTIDE OR POLYPEPTIDE, AS WELL AS METHODS FOR DETERMINING WHETHER A PARTICULAR SITE IN A TARGET MOLECULE IS AT OR NEAR THE LIGAND BINDING SITE, ARE PROVIDED. LIGAND BINDING AFFINITIES CORRESPONDING TO BOTH THE TARGET MOLECULE | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| EP-1381694-A1 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS Pharmaceuticals, Inc. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6653067-B1 | Contacting with modified/unmodified test molecule and dissociating; comparing the unseparated complexes; mass spectrometry; use in drug discovery | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030165915-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-20030077630-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20030013113-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002068691-A1 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | C5, C9, C1QBP | PDPK1 1081/4885GDA 1784/4885PI4KA 2356/4885 |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | PDPK1 4125/4885GDA 1617/4885PI4KA 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.